Lihui Lu
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
ATRX large deletions and truncating mutations are associated with primary induction chemotherapy resistance in high-risk neuroblastoma: a multicenter propensity-weighted cohort study.
Journal: Frontiers in oncology
Published: April 16, 2026
DKK3 as a novel biomarker for risk stratification in pediatric acute lymphoblastic leukemia.
Journal: Hematology (Amsterdam, Netherlands)
Published: November 12, 2025
BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Journal: Hematology (Amsterdam, Netherlands)
Published: August 18, 2023
Super Enhancer Regulatory Gene FYB1 Promotes the Progression of T Cell Acute Lymphoblastic Leukemia by Activating IGLL1.
Journal: Journal of immunology research
Published: October 22, 2022
LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.
Journal: Cell death & disease
Published: October 07, 2022
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Journal: Cancer biology & therapy
Published: September 28, 2022
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Journal: Journal of immunology research
Published: May 07, 2022
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
Journal: Pathology oncology research : POR
Published: March 17, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026